Funded Projects › H2020
RADAR-AD · Remote Assessment of Disease and Relapse – Alzheimer’s Disease
There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The system developed will be suitable for future longitudinal studies, including trials. The objectives are to 1) Identify the most relevant functional domains and the most promising remote measurement tools (RMTs) for these domains based on reviewing the literature and piloting of RMTs in small studies; 2) Optimise the RADAR-CNS platform for use in AD studies; 3) Test the platform and selected RMTs in a real world environment clinical study with 240 participants across the AD spectrum ranging from the preclinical AD to the dementia stage; 4) Perform statistical modelling to estimate longitudinal predictions; 5) Discuss results with regulatory agencies in order to obtain guidance about how to develop a path for formal qualification as outcome measurements in future therapeutic interventions. Considering the limited budget and project duration, we will rely upon already available technology platforms and on available longitudinal datasets where possible. The consortium includes experts in clinical dementia studies, computer science, bioinformatics, regulatory policies, ethics, and patient and public involvement (PPI). Additional strengths of the consortium are the deep and broad interface with RADAR-CNS and related IMI projects, and the access to large amount of patient-level data from key European cohort studies for modelling purposes.
Consortium · 17 organisations
KING'S COLLEGE LONDON
UK · €882,041
SOFTWARE AG
DE
ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
EL · €349,377
TAKEDA PHARMACEUTICALS INTERNATIONAL AG
CH
STICHTING LYGATURE
NL · €688,920
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
DE · €247,250
NOVARTIS PHARMA AG
CH
THE HYVE BV
NL · €467,203
TAKEDA DEVELOPMENT CENTRE EUROPE LTD
UK
STICHTING AMSTERDAM UMC
NL · €1,273,127
KAROLINSKA INSTITUTET
SE · €124,096
AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN
NL · €50,000
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
UK · €717,243
ELI LILLY AND COMPANY LTD
UK
ALZHEIMER EUROPE
LU · €200,500
ALTOIDA AG
CH
JANSSEN PHARMACEUTICA NV
BE
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.